Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trialJürgen C. Becker, Lucie Heinzerling, Imke Grimmelmann et al.|The Lancet|2023Cited by 75
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREGCindy Franklin, Selma Ugurel, Peter J. Mohr et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 19
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trialElisabeth Livingstone, Dirk Schadendorf, Helen Gogas et al.|European Journal of Cancer|2023Cited by 15
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGCindy Franklin, Selma Ugurel, Peter Mohr et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 14
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced <i>BRAF<sup>V600</sup></i>-positive melanoma: Interim analysis of the ImmunoCobiVem study.Dirk Schadendorf, Elisabeth Livingstone, Helen Gogas et al.|Journal of Clinical Oncology|2022Cited by 7